tbuckley/cabot-search huggingface dataset:
RT-37 * LONG TERM RESULTS OF GAMMA KNIFE RADIOSURGERY FOR GLOMUS TUMORS
Authors: A. Wolf, G. Renzi, H. Koss
Journal: Neuro-Oncology (2014)

INTRODUCTION: Paragangliomas (PGs) or glomus tumors are rare, vascular tumors that arise from chief cells in the paraganglia. Traditionally, standard treatment for these tumors includes microsurgical resection and conventional radiotherapy. Seven of the patients treated had previously undergone at least one microsurgical resection. Three underwent one surgery, one underwent two surgeries, one underwent three surgeries, one underwent one surgery and radiotherapy, and one underwent one surgery, radiotherapy, and a Gamma Knife procedure. Before the treatment, only one patient lacked cranial nerve deficit, while the others had at least one. We sought to analyze our data of PGs treated with Gamma Knife Radiosurgery. METHODS: We retrospectively examined the outcomes of 24 PGs in 24 patients treated with Gamma Knife Radiosurgery at the Miami Neuroscience Center. We collected data from medical records, imaging studies, and follow-up appointments. RESULTS: Patients were treated from 1993 to 2014. 87.5% (21) of the patients were female and 12.5% (3) were male. Volume of tumors ranged from 2.8 cc to 40.0 cc, with a mean of 14.7 cc. Doses to the tumors ranged from 10 to 20 cGy, with a mean of 12.8 cGy. One patient received staged treatment six months apart from each other, while every other patient received only one dose of treatment. Tumor control rates were 100%, with long term follow-ups ranging from 3 months to 240 months. No patients experienced additional cranial nerve deficit; in 3 patients there was significant improvement. CONCLUSION: We believe that Gamma Knife Radiosurgery is the optimal treatment for new and recurrent PGs. A common criticism of Gamma Knife Radiosurgery is the lack of long term results. However, with a sample size of 24 patients, median follow-ups of 65 months, and a 100% control rate to date, we believe that Gamma Knife is the best available treatment for paragangliomas.
RELATIONSHIP BETWEEN PERCENTAGE REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AMONG PATIENTS TREATED WITH STATINS +/- ALIROCUMAB OR EZETIMIBE IN THE PHASE 3 ODYSSEY TRIALS
Authors: Kausik Ray, Henry Ginsberg, Michael Davidson, Robert Pordy, Laurence Bessac, Pascal Minini, Robert Eckel, Christopher Cannon
Journal: Journal of the American College of Cardiology (2016)
Existe-t-il des facteurs prédictifs de la qualité de la préparation colique avant un examen endoscopique par vidéocapsule? Résultats d'une analyse post-hoc des données recueillies lors d'un PHRC national
Authors: C Garret, S Sacher-Huvelin, L Planche, R Benamouzig, S Chaussade, G Gay, M Gaudric, V Maunoury, B Filoche, M Frederic, JP Galmiche
Journal: Endoscopy (2012)

La Vidéocapsule colique (VCC) permet l'exploration du colon et la détection de polypes avec une sensibilité proche de la coloscopie pour le dispositif de seconde génération. Cependant, les performances diagnostiques sont directement liées à la qualité de la préparation colique (meilleure sensibilité en cas de préparation colique bonne ou excellente). Concernant la coloscopie conventionnelle, certains facteurs prédictifs de bonne préparation ont été identifiés. Toutefois, à ce jour, aucun facteur prédictif n'a été clairement identifié pour la préparation destinée à la VCC, même si des recommandations ont été émises sur la base d'un niveau de preuve assez faible. Le but de cette étude a été de rechercher par une analyse post-hoc d'éventuels facteurs prédictifs de qualité de la préparation colique avant VCC à partir de la cohorte de patients inclus prospectivement dans l'étude PHRC national VCC1a.
Cardiovascular Medicine at the Turn of the Millennium: Triumphs, Concerns, and Opportunities
Authors: Eugene Braunwald
Journal: New England Journal of Medicine (1997)

Tthe end of every century it is customary to reflect on the events of the past hundred years and to look toward the future, and in this lecture I should like to do this for cardiovascular disease. This is also an especially opportune time to comment on progress in cardiovascular disease, because both the National Heart, Lung, and Blood Institute and the American Heart Association are celebrating their golden anniversaries within the next 18 months. These two organizations have had the most profound influence on the development of research on cardiovascular disease during the 20th century. A bewildering amount of . . .
AB0587 Limitations of the 1990 American College of Rheumatology Criteria in the Classification of Cutaneous Vasculitis. Study of 773 Cutaneous Vasculitis
Authors: F. Ortiz-Sanjuán, R. Blanco, T. Pina, V. Calvo-Río, J. Loricera, L. Martín, L. Άlvarez, M.C. González-Vela, J. Rueda-Gotor, M.A. González-Lόpez, M.E. Peirό, M. Santos-Gόmez, M. Arias, M.A. González-Gay
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> In 1990 The American College of Rheumatology (ACR) established criteria for the classification of vasculitis. Cutaneous vasculitis (CV) comprises a wide and heterogeneous group of entities. <h3>Objectives</h3> Our aim was to revise the usefulness of ACR-1990 criteria in classifying patients with CV. <h3>Methods</h3> Retrospective study of a wide and unselected series of patients with CV from a single university hospital from January 1976 to January 2012. Patients were classified according to the 1990 ACR methodology and criteria. <h3>Results</h3> 773 Patients (351 women/422 men) with a mean age of 34.1±27.4 years were diagnosed as having CV. Applying the 1990 ACR criteria patients were classified as secondary to connective tissue diseases (n=35), major infections (n=27), malignancies (n=16), mixed essential cryoglobulinemia (n=13), Wegener Granulomatosis (n=3), Churg-Strauss syndrome (n=3) and Polyarteritis nodosa (n=3). The remaining 673 patients were classified as Hipersensitivity vasculitis (n=247; 36.6%) or Henoch Schönlein Purpura (n=414; 61.4%). Disappointingly, 127 (18.8%) met criteria for both entities and 12 out of 673 cases did not meet criteria for HV nor HSP and were not classified. <h3>Conclusions</h3> The ACR-1990 criteria for vasculitis do not properly classify patients with CV. <h3>Acknowledgements</h3> This study was supported by a grant from “Fondo de Investigaciones Sanitarias” PI12/00193 (Spain). This work was also partially supported by RETICS Programs, RD08/0075 (RIER) and RD12/0009/0013 from “Instituto de Salud Carlos III” (ISCIII) (Spain). <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3111
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal
Authors: Monika Haemmerle, Justin Bottsford-Miller, Sunila Pradeep, Morgan L. Taylor, Hyun-Jin Choi, Jean M. Hansen, Heather J. Dalton, Rebecca L. Stone, Min Soon Cho, Alpa M. Nick, Archana S. Nagaraja, Tony Gutschner, Kshipra M. Gharpure, Lingegowda S. Mangala, Rajesha Rupaimoole, Hee Dong Han, Behrouz Zand, Guillermo N. Armaiz-Pena, Sherry Y. Wu, Chad V. Pecot, Alan R. Burns, Gabriel Lopez-Berestein, Vahid Afshar-Kharghan, Anil K. Sood
Journal: Journal of Clinical Investigation (2016)

Recent studies in patients with ovarian cancer suggest that tumor growth may be accelerated following cessation of antiangiogenesis therapy; however, the underlying mechanisms are not well understood. In this study, we aimed to compare the effects of therapy withdrawal to those of continuous treatment with various antiangiogenic agents. Cessation of therapy with pazopanib, bevacizumab, and the human and murine anti-VEGF antibody B20 was associated with substantial tumor growth in mouse models of ovarian cancer. Increased tumor growth was accompanied by tumor hypoxia, increased tumor angiogenesis, and vascular leakage. Moreover, we found hypoxia-induced ADP production and platelet infiltration into tumors after withdrawal of antiangiogenic therapy, and lowering platelet counts markedly inhibited tumor rebound after withdrawal of antiangiogenic therapy. Focal adhesion kinase (FAK) in platelets regulated their migration into the tumor microenvironment, and FAK-deficient platelets completely prevented the rebound tumor growth. Additionally, combined therapy with a FAK inhibitor and the antiangiogenic agents pazopanib and bevacizumab reduced tumor growth and inhibited negative effects following withdrawal of antiangiogenic therapy. In summary, these results suggest that FAK may be a unique target in situations in which antiangiogenic agents are withdrawn, and dual targeting of FAK and VEGF could have therapeutic implications for ovarian cancer management.
Adverse Nondrug Reactions
Authors: Marcus M. Reidenberg, David T. Lowenthal, R. Sacks
Journal: New England Journal of Medicine (1968)

Healthy university students and hospital staff taking no medications were surveyed by questionnaire to obtain data on the occurrence of many symptoms often listed as side effects of drugs. Of 670 people surveyed, 414 indicated that they had had no illnesses and taken no medications during the previous three days and were included in the study. Only 19 per cent of the 414 stated that they had experienced none of 25 symptoms listed in the previous 72 hours. The median number of symptoms experienced per person was two. Thirty people experienced six or more of these symptoms. In the study of adverse drug reactions proper controls are just as important as in any other form of research.
1274 MORBIDLY OBESE PATIENTS WITH ALANINE AMINOTRANSFERASE (ALT) LEVEL BELOW THE THRESHOLD 0.5 TIMES THE UPPER LIMIT OF NORMAL HAVE NO NASH
Authors: R. Anty, A. Iannelli, S. Patouraux, S. Bonnafous, V. Lavallard, E. Marine-Barjoan, A.-S. Schneck, M.C. Saint Paul, P.M. Huet, Y. Le Marchand-Brustel, J. Gugenheim, P. Gual, A. Tran
Journal: Journal of Hepatology (2012)
Abstract 781: Bioconversion of curcumin and its analog by <i>Beauveria bassiana</i> ATCC 7159
Authors: Glenroy Martin, Tamara Ebert, Jennifer McPhee, Bettie Mercer, Jesica Williams
Journal: Cancer Research (2010)

Abstract Curcumin (1), a chemopreventive agent from turmeric (Curcuma longa L.) was incubated with the microbial cultures of Beauveria bassiana ATCC 7159. Bioconversion of [(1E, 6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione] (1) with B. bassiana afforded five major metabolites: 1,7-bis(4-hydroxyphenyl)heptane-3,5-dione (2), 3-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hept-1-ene (3), 1,2,6,7-diepoxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-3,5-diol (4), 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hept-1-ene (5) and 1,7-bis(4-hydroxy-3-methoxyphenyl)heptan-3,5-diol (6). The biotransformation of the synthetic analog 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-dione (7) by B. bassiana afforded the reduced diol 1,7-bis(4-hydroxy-3-methoxyphenyl)heptan-3,5-diol (6) as the only metabolite. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 781.
Abstract LB-275: Genome-wide analysis of the vitamin D receptor (VDR) binding sites reveals vitamin D role mediating autophagy in luminal-like breast cancer cells
Authors: Luz E. Tavera, Thomas Westerling, Myles Brown
Journal: Cancer Research (2012)

Abstract The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25D3), regulates gene expression through the vitamin D receptor (VDR). Even though 1,25D3 is still best known as a regulator of bodily calcium homeostasis, 1,25D3 has a plethora of physiological actions which include immune and nervous system modulation, cellular proliferation and differentiation. Epidemiological and model studies have revealed the cancer-protective properties of 1,25D3 in colon, prostate and notably in breast. We are actively investigating the anti-proliferative properties of 1,25D3 in a panel of human breast cancer cell lines. We found that 1,25D3 induces autophagy in several luminal-like breast cancer cell models, but not in basal-like or mesenchymal-like models. We performed VDR and signaling partner RXR whole-genome ChIP-seq analysis to uncover all of the direct 1,25D3 target genes involved in regulation of metabolism and autophagy. Our preliminary studies suggest that energy regulation as an important aspect of 1,25D3 anti-proliferative properties in luminal-like breast cancer cells Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-275. doi:1538-7445.AM2012-LB-275
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
Authors: V Madan, P Shyamsunder, L Han, A Mayakonda, Y Nagata, J Sundaresan, D Kanojia, K Yoshida, S Ganesan, N Hattori, N Fulton, K-T Tan, T Alpermann, M-C Kuo, S Rostami, J Matthews, M Sanada, L-Z Liu, Y Shiraishi, S Miyano, E Chendamarai, H-A Hou, G Malnassy, T Ma, M Garg, L-W Ding, Q-Y Sun, W Chien, T Ikezoe, M Lill, A Biondi, R A Larson, B L Powell, M Lübbert, W J Chng, H-F Tien, M Heuser, A Ganser, M Koren-Michowitz, S M Kornblau, H M Kantarjian, D Nowak, W-K Hofmann, H Yang, W Stock, A Ghavamzadeh, K Alimoghaddam, T Haferlach, S Ogawa, L-Y Shih, V Mathews, H P Koeffler
Journal: Leukemia (2016)

Acute promyelocytic leukemia (APL) is a subtype of myeloid leukemia characterized by differentiation block at the promyelocyte stage. Besides the presence of chromosomal rearrangement t(15;17), leading to the formation of PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) fusion, other genetic alterations have also been implicated in APL. Here, we performed comprehensive mutational analysis of primary and relapse APL to identify somatic alterations, which cooperate with PML-RARA in the pathogenesis of APL. We explored the mutational landscape using whole-exome (n=12) and subsequent targeted sequencing of 398 genes in 153 primary and 69 relapse APL. Both primary and relapse APL harbored an average of eight non-silent somatic mutations per exome. We observed recurrent alterations of FLT3, WT1, NRAS and KRAS in the newly diagnosed APL, whereas mutations in other genes commonly mutated in myeloid leukemia were rarely detected. The molecular signature of APL relapse was characterized by emergence of frequent mutations in PML and RARA genes. Our sequencing data also demonstrates incidence of loss-of-function mutations in previously unidentified genes, ARID1B and ARID1A, both of which encode for key components of the SWI/SNF complex. We show that knockdown of ARID1B in APL cell line, NB4, results in large-scale activation of gene expression and reduced in vitro differentiation potential.
Abstract 102: Functional characterization of long noncoding RNA SPRY4-IT1 in human melanomas
Authors: Wei Zhao, Joseph Mazar, Ranjan J. Perera
Journal: Cancer Research (2012)

Abstract Recently, we have reported that long noncoding RNA SPRY4-IT1 (Khaitan et al., Cancer Research 2011) is highly upregulated in human melanomas compared to melanocytes and keratinocytes. The elevated expression of SPRY4-IT1 in melanoma cells compared to melanocytes, its accumulation in cell cytoplasm, and effects on cell dynamics, including increased rate of wound closure upon SPRY4-IT1 overexpression, suggest that the higher expression of SPRY4-IT1 may have an important role in the molecular etiology of human melanoma. We have now engineered melanocytes to ectopically express SPRY4-IT1 and engineered cells were assayed to identify gene and protein expression changes compared to vector only cells. We observed that engineered cells show higher cell proliferation rate compared to vector only cells. Melanoma cells were treated with α-amenitin to identify the half-life of both SPRY4 and SPRY4-IT1, and our results indicate that SPRY4-IT1 has a higher RNA decay compared to its host gene SPRY4. Isolation of monosome and polysome fractions followed by qRT-PCR shows that SPRY4-IT1 is primarily transported in to the polysome fraction. Finally, we have demonstrated that SPRY4-IT1 transcriptional regulation is independent of SPRY4 gene. SPRY4-IT1 molecular function, transcriptional regulation, cellular compartmentalization, interaction with other RNAs and proteins will be discussed. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 102. doi:1538-7445.AM2012-102
Abstract 3430: Snail1 regulates invasion through uPA-uPAR signaling in prostate cancer
Authors: Diandra D. Randle, Valerie Odero-Marah
Journal: Cancer Research (2011)

Abstract PURPOSE: Epithelial-mesenchymal transition (EMT) is a process by which cancer cells acquire mesenchymal properties, such as induction of N-cadherin, while epithelial-associated genes like E-cadherin are lost. This enables the cells to be more invasive, migratory and metastatic. Factors that can induce EMT include growth factors like transforming growth factor -β (TGF-β) and epidermal growth factor (EGF), and transcription factors like Snail1. Snail1-induced EMT promotes migration and invasion and we hypothesized that this may be mediated by urokinase (uPA) and its receptor (uPAR) activities. uPA, a serine protease, may be activated by integrin engagement to bind to its receptor, uPAR, and initiate a signaling cascade that regulates a variety of biological pathways including migration and invasion. DESIGN METHODS: 22Rv1, LNCaP and ARCaP human prostate cancer (PC) cells were stably transfected with empty vector control (Neo) or constitutively active Snail which led to increased cell migration and invasion. The levels of Snail, uPA, and uPAR were measured by Western Blot analysis. uPA activity in conditioned media was measured using the Elisa uPA activity assay kit. Also, cells were treated with PI3K and MAPK inhibitors at set time points. RESULTS: The data suggests that overexpression of Snail1 increased uPA and uPAR protein levels, while uPA activity was elevated in conditioned media from ARCaP, LNCaP and 22Rv1 cells transfected with Snail. In addition, MAPK inhibitor, UO126, inhibited ERK activity within 30 min up to 72 h, and decreased uPA activity within 24 h. CONCLUSION: Therefore, Snail-mediated cell migration and invasion in human prostate cancer cells may occur via the regulation of uPA/uPAR and MAPK activities. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3430. doi:10.1158/1538-7445.AM2011-3430
A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis
Authors: Mark Levine, Michael Gent, Jack Hirsh, Jacques Leclerc, David Anderson, Jeffrey Weitz, Jeffrey Ginsberg, Alexander G. Turpie, Christine Demers, Michael Kovacs, William Geerts, Jeanine Kassis, Louis Desjardins, Jean Cusson, Moira Cruickshank, Peter Powers, William Brien, Susan Haley, Andrew Willan
Journal: New England Journal of Medicine (1996)

Patients with acute proximal deep-vein thrombosis are usually treated first in the hospital with intravenous standard (unfractionated) heparin. However, the longer plasma half-life, better bioavailability after subcutaneous administration, and more predictable anticoagulant response of low-molecular-weight heparins make them attractive for possible home use. We compared these two approaches.
Esophageal papillomatosis complicated by squamous cell carcinoma
Authors: F. Donnellan, B. Walker, R. Enns
Journal: Endoscopy (2012)

A 64-year-old woman was referred for investigation of a thickened esophagus on computed tomography (CT) scanning. She had no upper gastrointestinal symptoms, in particular, any dysphagia or weight loss. Nine years previously she had undergone a bone marrow transplant for myelodysplasia for which she was taking 5 mg prednisolone. Endoscopy with a GIF-Q180 gastroscope (Olympus, Tokyo, Japan) demonstrated a circumferential area of multiple confluent papules extending for 5 cm in the mid-esophagus, with a 2-cm nodule at its distal border. The remainder of the esophagus was normal ([Fig. 1], [Video 1]). Histological examination revealed atypical squamous epithelial proliferation, consistent with papillomatosis, and evidence of invasive squamous cell carcinoma in the nodule ([Fig. 2], [Video 1]). Studies to identify human papillomavirus (HPV) as potential etiology were not performed. The patient has been referred for chemoradiotherapy.
AB0641 Urinary CXCL-10 and MCP-1 are good markers to assess activity of lupus nephritis:
Authors: B. Abujam, S.S. Cheekatla, A. Aggarwal
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Interferon-γ-inducible protein 10 (IP-10) or chemokine (C-X-C motif) ligand 10 (CXCL 10) and Monocyte chemo-attractant protein-1 (MCP- 1) are chemokines involved in immune pathogenesis of lupus nephritis and may be useful biomarkers. <h3>Objectives</h3> To look at the utility of serum and urinary IP-10 and MCP-1 as biomarkers for lupus generalised and renal activity. <h3>Methods</h3> SLE patients fulfilling ACR 1997 criteria (both adult and children) were recruited and blood and urine samples collected. Disease activity was assessed by SLEDAI and active lupus defined as SLEDAI ≥4. Active patients further divided into active renal and active non-renal lupus based on urinary parameters (proteinuria ≥500 mg/day or active sediment in urine). Kidney biopsy was done in some cases as per the treating physician's decision or patient consent. Patients with active renal lupus were followed until disease became inactive. Healthy controls also reruited. Serum and urinary levels of MCP-1 and IP-10 (pg/ml) were measured by ELISA. Urinary values were normalised for urinary creatinine. Data presented as median (interquartile range). Mann Whitney U test, kruskal-wallis used to compare median levels between groups. Paired t test used to compare longitudinal values. <h3>Results</h3> Study included 136 patients with SLE including 78 active (46 active renal and 32 active non renal). Median age was 25 (10-55) years and SLE duration was 23 (6-48) months. Serum and urinary levels of MCP-1 and IP-10 were higher in active compared to inactive SLE as well as healthy controls (Table 1). However, in active renal compared to active non-renal SLE, only urinary but not serum levels of MCP-1 and IP-10 were higher (Table 1). Out of the 46 renal active patients, kidney biopsy done in 31: class IV 25, class III 4, class V 2. If consider only biopsy proven proliferative nephritis as "true active renal", still urinary MCP-1 and IP-10 higher compared to both inactive and active non renal patients (p=0.003, 0.023). On ROC analysis, urinary MCP-1 better as compared to urinary IP-10 for differentiating active renal from active non renal SLE [p=0.03], in addition, urinary MCP-1 better than C4 [p&lt;0.05]. On longitudinal follow up of active renal patients (n=24) urinary levels of MCP-1 and IP-10 [p=0.005] and serum levels of IP-10 [p=0.003] decreased. <h3>Conclusions</h3> Urinary and serum IP-10 and MCP-1 are good markers of lupus activity. Importantly, urinary levels can differentiate renal from non-renal active disease and can be used for follow up of lupus nephritis patients. <h3>Disclosure of Interest</h3> None Declared
311 EX VIVO-EXPANDED PERIPHERAL CD34+ CELLS FOR CHRONICALLY INJURED LIVER TREATMENT: IN VITRO AND IN VIVO STUDIES
Authors: T. Nakamura, T. Torimura, H. Masuda, H. Iwamoto, O. Hashimoto, H. Koga, M. Abe, Y. Ikezono, T. Ueno, M. Sata
Journal: Journal of Hepatology (2013)